

Catherine Thieblemont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7152991/publications.pdf>

Version: 2024-02-01

338
papers

19,654
citations

11651
70
h-index

13379
130
g-index

345
all docs

345
docs citations

345
times ranked

14576
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 2010, 116, 2040-2045.	1.4	1,193
2	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genetics, 2014, 46, 171-175.	21.4	542
3	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood, 2000, 95, 802-806.	1.4	484
4	Treatment of Older Patients with Mantle-Cell Lymphoma. New England Journal of Medicine, 2012, 367, 520-531.	27.0	465
5	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2011, 12, 460-468.	10.7	420
6	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.	1.4	391
7	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 1285-1295.	1.6	388
8	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematology, the, 2016, 3, e196-e204.	4.6	344
9	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016, 388, 565-575.	13.7	328
10	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 1250-1260.	27.0	313
11	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. Lancet, The, 2011, 378, 1858-1867.	13.7	311
12	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood, 2011, 118, 37-43.	1.4	280
13	Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood, 2000, 95, 1950-1956.	1.4	279
14	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 351-363.	27.0	278
15	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2019, 37, 1188-1199.	1.6	277
16	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of Clinical Oncology, 2016, 34, 1386-1394.	1.6	276
17	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of Oncology, 2013, 24, 857-877.	1.2	268
18	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNHO3-6B study): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 525-533.	10.7	257

#	ARTICLE	IF	CITATIONS
19	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	1.2	249
20	The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4079-4087.	1.6	248
21	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 1019-1026.	10.7	246
22	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	1.4	243
23	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	27.0	243
24	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 787-792.	1.6	239
25	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 5607-5615.	5.2	222
26	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	10.7	222
27	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016, 51, 51-57.	2.4	216
28	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2169-2178.	1.2	207
29	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e511-e522.	4.6	201
30	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	1.6	198
31	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 17-29.	1.2	197
32	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3291-3299.	1.6	195
33	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
34	Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2912-2919.	1.6	185
35	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	30.7	182
36	Alteration of BIRC3 and multiple other NF- κ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011, 118, 4930-4934.	1.4	176

#	ARTICLE	IF	CITATIONS
37	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. <i>Blood</i> , 2012, 119, 5126-5132.	1.4	175
38	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010, 116, 1479-1488.	1.4	174
39	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	1.4	173
40	Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. <i>Lancet Oncology</i> , The, 2003, 4, 95-103.	10.7	161
41	Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome. <i>Nature Genetics</i> , 2018, 50, 1650-1657.	21.4	151
42	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	1.4	149
43	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 41-47.	2.1	148
44	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	1.6	148
45	MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012, 119, 4619-4624.	1.4	145
46	Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 920-926.	3.9	144
47	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
48	Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2920-2926.	1.6	137
49	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014, 32, 1338-1346.	1.6	137
50	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	7.4	136
51	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
52	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	1.4	130
53	Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. <i>Blood</i> , 2015, 126, 1695-1698.	1.4	126
54	Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. <i>Blood</i> , 2010, 116, 5119-5125.	1.4	123

#	ARTICLE	IF	CITATIONS
55	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104.	1.4	122
56	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	1.4	119
57	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. <i>European Journal of Cancer</i> , 2013, 49, 2869-2876.	2.8	114
58	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	30.7	114
59	Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival. <i>PLoS ONE</i> , 2013, 8, e55870.	2.5	108
60	Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. <i>Targeted Oncology</i> , 2020, 15, 249-259.	3.6	108
61	Clinical Presentation and Management of Marginal Zone Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 307-313.	2.5	102
62	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017, 52, 216-221.	2.4	102
63	A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. <i>Journal of Nuclear Medicine</i> , 2022, 63, 172-179.	5.0	96
64	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015, 2, e160-e165.	4.6	95
65	Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Oncologique. <i>British Journal of Haematology</i> , 2013, 162, 489-497.	2.5	90
66	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
67	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	2.5	88
68	FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017, 130, 1315-1326.	1.4	87
69	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lymphoC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	4.1	84
70	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 1854-1860.	1.3	83
71	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014, 24, 33-42.	9.6	80
72	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	1.6	79

#	ARTICLE	IF	CITATIONS
73	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. <i>Annals of Oncology</i> , 2013, 24, 1344-1351.	1.2	75
74	Deep-Learning ¹⁸ F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 30-36.	5.0	75
75	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	1.6	73
76	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2016, 55, 397-405.	3.5	72
77	Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 43-54.	2.0	70
78	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	8.1	70
79	Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. <i>Blood</i> , 2021, 138, 81-83.	1.4	70
80	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018, 32, 1799-1803.	7.2	67
81	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	5.2	67
82	Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. <i>Haematologica</i> , 2005, 90, 470-8.	3.5	67
83	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	4.6	64
84	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016, 47, 1244-1260.	6.7	60
85	Optimizing therapy for nodal marginal zone lymphoma. <i>Blood</i> , 2016, 127, 2064-2071.	1.4	59
86	Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. <i>Leukemia</i> , 2018, 32, 2590-2603.	7.2	59
87	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019, 29, 1243-1257.e10.	16.2	56
88	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF- κ B-dependent induction of HIF-1 α . <i>Leukemia</i> , 2015, 29, 1163-1176.	7.2	55
89	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 390-397.	1.2	54
90	Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 390-400.	2.5	53

#	ARTICLE	IF	CITATIONS
91	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	1.4	53
92	Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 262-269.	0.4	52
93	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	3.7	52
94	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). <i>Blood</i> , 2012, 120, 151-151.	1.4	52
95	Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity?. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 220-224.	2.1	50
96	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , 2016, 101, 336-345.	3.5	50
97	A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 722-730.	2.5	49
98	NF- κ B in the New Era of Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 677-687.	7.4	49
99	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	1.4	49
100	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. <i>Annals of Oncology</i> , 2012, 23, 2380-2385.	1.2	48
101	Efficacy of ibrutinib in the treatment of B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2016, 91, E17-9.	4.1	48
102	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	1.4	48
103	Inhibitors of BCR signalling interrupt the survival signal mediated by the microenvironment in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2015, 136, 2761-2774.	5.1	47
104	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 388-398.	2.5	47
105	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 365-371.	2.4	43
106	Clinical aspects and therapy of gastrointestinal MALT lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 109-117.	1.7	42
107	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	7.0	42
108	Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 243-243.	1.4	42

#	ARTICLE	IF	CITATIONS
109	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	4.1	41
110	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	2.5	41
111	Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 884-884.	1.4	41
112	G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 2347-2349.	2.4	40
113	MALT lymphomas: pathogenesis can drive treatment. Oncology, 2011, 25, 1134-42, 1147.	0.5	40
114	Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Journal of Clinical Oncology, 2021, 39, 1203-1213.	1.6	39
115	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica, 2016, 101, e407-e410.	3.5	38
116	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. Blood, 2016, 128, 145-145.	1.4	38
117	Targeting of B-cell receptor signalling in B-cell malignancies. Journal of Internal Medicine, 2017, 282, 415-428.	6.0	37
118	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 2005, 104, 1434-1441.	4.1	35
119	A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2863-2869.	1.3	33
120	Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer Journal, 2020, 10, 62.	6.2	32
121	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Annals of Oncology, 2013, 24, 1032-1037.	1.2	31
122	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica, 2020, 105, e33-e36.	3.5	31
123	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Annals of Oncology, 2013, 24, 2612-2618.	1.2	30
124	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. Leukemia and Lymphoma, 2003, 44, 257-262.	1.3	29
125	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica, 2020, 105, 2592-2597.	3.5	29
126	Second-line treatment paradigms for diffuse large B-cell lymphomas. Current Oncology Reports, 2009, 11, 386-393.	4.0	27

#	ARTICLE	IF	CITATIONS
127	Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2287-2293.	2.0	27
128	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	4.6	27
129	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	27
130	The Need for a Consensus Next-Generation Sequencing Panel for Mature Lymphoid Malignancies. <i>HemaSphere</i> , 2019, 3, e169.	2.7	26
131	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	2.4	26
132	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 431-439.	2.4	26
133	Non-MALT marginal zone lymphoma. <i>Current Opinion in Hematology</i> , 2011, 18, 273-279.	2.5	25
134	MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. <i>Blood</i> , 2013, 121, 2165-2166.	1.4	25
135	Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). <i>Digestive and Liver Disease</i> , 2018, 50, 124-131.	0.9	25
136	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	1.4	25
137	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 371-378.	2.5	24
138	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	1.4	24
139	Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. <i>Cancer Research</i> , 2014, 74, CT231-CT231.	0.9	23
140	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	1.8	22
141	Discovery of Human-Similar Gene Fusions in Canine Cancers. <i>Cancer Research</i> , 2017, 77, 5721-5727.	0.9	22
142	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	1.2	21
143	Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. <i>Annals of Hematology</i> , 2015, 94, 89-95.	1.8	20
144	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. <i>Oncotarget</i> , 2016, 7, 83987-84002.	1.8	20

#	ARTICLE	IF	CITATIONS
145	Splenic marginal zone lymphoma: current knowledge and future directions. <i>Oncology</i> , 2012, 26, 194-202.	0.5	20
146	At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. <i>European Journal of Immunology</i> , 2013, 43, 1383-1388.	2.9	19
147	Treatment of Follicular Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 31-37.	0.8	19
148	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	2.5	19
149	Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study. <i>Blood</i> , 2014, 124, 146-146.	1.4	19
150	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 338-338.	1.4	19
151	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.5	19
152	Lenalidomide in Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	1.0	18
153	Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1240-1245.	1.3	18
154	Burden of illness of follicular lymphoma and marginal zone lymphoma. <i>Annals of Hematology</i> , 2019, 98, 175-183.	1.8	18
155	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. <i>Annals of Hematology</i> , 2014, 93, 233-242.	1.8	17
156	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	17.0	17
157	Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 151-154.	0.4	16
158	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 784-784.	1.4	16
159	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4196-4196.	1.4	16
160	Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006. <i>International Journal of Cancer</i> , 2015, 137, 1217-1223.	5.1	15
161	Optimizing initial therapy in DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 199-208.	1.7	15
162	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2020, 55, 613-622.	2.4	15

#	ARTICLE	IF	CITATIONS
163	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	2.5	15
164	Stabilization of β^2 -catenin upon B-cell receptor signaling promotes NF- κ B target genes transcription in mantle cell lymphoma. <i>Oncogene</i> , 2020, 39, 2934-2947.	5.9	15
165	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3067-3067.	1.4	15
166	Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2362-2367.	1.3	14
167	Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. <i>Annals of Oncology</i> , 2017, 28, 2680-2690.	1.2	14
168	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019, 125, 2291-2299.	4.1	14
169	Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. <i>Journal of Dermatology</i> , 2021, 48, e49-e71.	1.2	14
170	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216.	0.9	14
171	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018, 132, 228-228.	1.4	14
172	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. <i>Annals of Oncology</i> , 2016, 27, 1349-1350.	1.2	13
173	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 115.	2.4	13
174	Earlier Steroid Use with Axicabtagene Ciloleuce (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101.	2.0	13
175	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 827-839.	1.3	13
176	HHV-6 reactivation as a cause of fever in autologous hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2017, 75, 155-159.	3.3	13
177	Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial. <i>Blood</i> , 2020, 136, 28-30.	1.4	13
178	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. <i>Blood</i> , 2012, 120, 152-152.	1.4	13
179	Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. <i>British Journal of Haematology</i> , 2014, 166, 306-308.	2.5	12
180	Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. <i>Oncotarget</i> , 2017, 8, 80073-80082.	1.8	12

#	ARTICLE	IF	CITATIONS
181	Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. <i>Lancet Haematology</i> , 2020, 7, e798-e807.	4.6	12
182	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. <i>Haematologica</i> , 2021, 106, 859-862.	3.5	12
183	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. <i>Cancers</i> , 2021, 13, 3998.	3.7	12
184	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016, 128, 471-471.	1.4	12
185	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021, 138, 739-739.	1.4	12
186	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	2.4	12
187	Human Herpesvirus-6 Cytopathic Inclusions. <i>American Journal of Dermatopathology</i> , 2012, 34, e73-e76.	0.6	11
188	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. <i>European Respiratory Journal</i> , 2016, 48, 1252-1252.	6.7	11
189	Rituximab + ABVD for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. <i>British Journal of Haematology</i> , 2016, 175, 735-737.	2.5	11
190	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 111.	17.0	11
191	Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 162, 846-848.	2.5	10
192	Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2023-2030.	6.4	10
193	Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3090-3095.	1.3	10
194	Management of aggressive lymphoma in very elderly patients. <i>Hematological Oncology</i> , 2017, 35, 49-53.	1.7	10
195	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. <i>Cancer Medicine</i> , 2018, 7, 539-548.	2.8	10
196	Curing diffuse large B-cell lymphomas in elderly patients. <i>European Journal of Internal Medicine</i> , 2018, 58, 14-21.	2.2	10
197	Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study. <i>Annals of Hematology</i> , 2020, 99, 1615-1625.	1.8	10
198	Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 7508-7508.	1.6	10

#	ARTICLE	IF	CITATIONS
199	Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. <i>Annals of Hematology</i> , 2021, 100, 979-986.	1.8	9
200	Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2016, 128, 1213-1213.	1.4	9
201	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021, 138, 430-430.	1.4	9
202	Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021, 138, LBA-6-LBA-6.	1.4	9
203	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. <i>Diagnostics</i> , 2022, 12, 417.	2.6	9
204	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2063-2073.	1.3	9
205	Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Neurology</i> , 2022, 99, 511-515.	1.1	9
206	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , 2020, 80, 219-224.	3.3	8
207	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. <i>Annals of Hematology</i> , 2020, 99, 1771-1778.	1.8	8
208	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	2.5	8
209	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	5.2	8
210	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013, 122, 764-764.	1.4	8
211	A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4458-4458.	1.4	8
212	Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. <i>Oncotarget</i> , 2017, 8, 16243-16258.	1.8	8
213	Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas. <i>Blood</i> , 2021, 138, 1433-1433.	1.4	8
214	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	1.4	8
215	Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 237-244.	2.0	7
216	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. <i>Seminars in Hematology</i> , 2018, 55, 179-181.	3.4	7

#	ARTICLE	IF	CITATIONS
217	JSH practical guidelines for hematological malignancies, 2018; II. Lymphoma-1. Follicular lymphoma (FL). International Journal of Hematology, 2019, 110, 11-19.	1.6	7
218	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. American Journal of Hematology, 2021, 96, E311-E314.	4.1	7
219	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. Cancers, 2021, 13, 4503.	3.7	7
220	Sub-Cutaneous Rituximab-Minichop Versus Sub-Cutaneous Rituximab-Minichop + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More (SENIOR Study). a Multicentric Randomized Phase III Study of the Lysa. Blood, 2019, 134, 352-352.	1.4	7
221	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. Blood, 2014, 124, 4417-4417.	1.4	7
222	A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry. Blood, 2021, 138, 92-92.	1.4	7
223	Comparing apples and oranges: The ZUMA-1, TRANSFORM and BELINDA trials. Hematological Oncology, 2022, 40, 1090-1093.	1.7	7
224	PET-driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP. British Journal of Haematology, 2015, 170, 278-281.	2.5	6
225	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. Leukemia and Lymphoma, 2015, 56, 2025-2031.	1.3	6
226	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1561-1572.	4.2	6
227	Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide+rituximab (R2) vs. rituximab+placebo in relapsed/refractory indolent non-Hodgkin lymphoma. International Journal of Hematology, 2020, 111, 409-416.	1.6	6
228	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplantation, 2021, 56, 1700-1709.	2.4	6
229	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. Future Oncology, 2021, 17, 1295-1310.	2.4	6
230	Phase I/II Study of IPH1101, 1st T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.. Blood, 2009, 114, 1649-1649.	1.4	6
231	An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,. Blood, 2011, 118, 3715-3715.	1.4	6
232	Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. Blood, 2014, 124, 678-678.	1.4	6
233	BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. Modern Pathology, 2012, 25, 805-814.	5.5	5
234	Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. Annals of Hematology, 2019, 98, 195-203.	1.8	5

#	ARTICLE	IF	CITATIONS
235	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <scp>LYSA</scp> group. Hematological Oncology, 2020, 38, 446-455.	1.7	5
236	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/<scp>Tâ€Cell</scp> lymphoma, nasal type: A French study from the Soci��t�� Francophone de Greffe de Moelle et de Th��rapie Cellulaire (<scp>SFGM��TC</scp>). American Journal of Hematology, 2021, 96, 834-845.	4.1	5
237	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	5
238	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. Blood, 2011, 118, 2632-2632.	1.4	5
239	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 1532-1532.	1.4	5
240	Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry. Blood, 2021, 138, 885-885.	1.4	5
241	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). Blood, 2021, 138, 306-306.	1.4	5
242	The Alternative RelB NF-��B Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells. Biomedicines, 2022, 10, 348.	3.2	5
243	Non-gastric extranodal marginal zone lymphomas: a challenge in routine practice. Leukemia and Lymphoma, 2008, 49, 2229-2230.	1.3	4
244	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1135-1143.	2.3	4
245	Therapy��related classical <scp>H</scp>odgkin lymphoma after a primary haematological malignancy: a report on 13 cases. British Journal of Haematology, 2012, 158, 644-648.	2.5	4
246	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. Annals of Hematology, 2015, 94, 1859-1863.	1.8	4
247	Definition of a minimal genes set for mature lymphoid blood diseases. Hematologie, 2018, 24, 27-59.	0.0	4
248	Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. PharmacoEconomics - Open, 2020, 4, 575-591.	1.8	4
249	Clinicopathological analysis of primary refractory diffuse large B��cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Cancer Medicine, 2021, 10, 5101-5109.	2.8	4
250	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). Blood, 2021, 138, 2832-2832.	1.4	4
251	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. Bone Marrow Transplantation, 2022, 57, 627-632.	2.4	4
252	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine, 2022, 11, 3541.	2.4	4

#	ARTICLE	IF	CITATIONS
253	Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?. British Journal of Haematology, 2018, 180, 304-308.	2.5	3
254	Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study. Japanese Journal of Clinical Oncology, 2018, 48, 736-742.	1.3	3
255	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. Hematological Oncology, 2019, 37, 244-245.	1.7	3
256	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. Molecular Cancer Therapeutics, 2020, 19, 2371-2381.	4.1	3
257	Prevalence, distribution and predictive value of <i>XPO1</i> mutation in a real-life chronic lymphocytic leukaemia cohort. British Journal of Haematology, 2020, 191, e90-e94.	2.5	3
258	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. Leukemia and Lymphoma, 2020, 61, 887-895.	1.3	3
259	CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL. Journal of Clinical Oncology, 2021, 39, 7543-7543.	1.6	3
260	Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA. Journal of Clinical Oncology, 2021, 39, 7544-7544.	1.6	3
261	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 5310-5310.	1.4	3
262	Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL). Blood, 2010, 116, 2860-2860.	1.4	3
263	Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). Blood, 2011, 118, 268-268.	1.4	3
264	VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. Oncotarget, 2017, 8, 90808-90824.	1.8	3
265	Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma. World Journal of Gastrointestinal Oncology, 2021, 13, 1453-1465.	2.0	3
266	Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.. Blood, 2008, 112, 1780-1780.	1.4	3
267	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. Blood, 2021, 138, 3528-3528.	1.4	3
268	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. Leukemia and Lymphoma, 2022, 63, 1058-1069.	1.3	3
269	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials. Leukemia and Lymphoma, 2022, 63, 1544-1555.	1.3	3
270	Treatment for patients with indolent and mantle cell lymphoma. Lancet, The, 2013, 382, 1094.	13.7	2

#	ARTICLE	IF	CITATIONS
271	Abstract CT132: A Phase 2b randomized study of selinexor in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) demonstrates durable responses in both GCB & Non-GCB subtypes. , 2017, , .		2
272	A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untreated Follicular B-Cell Lymphoma in Need of Systemic Therapy. Blood, 2018, 132, 446-446.	1.4	2
273	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922.	1.4	2
274	Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. Blood, 2018, 132, 1677-1677.	1.4	2
275	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 2019, 134, 347-347.	1.4	2
276	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. Blood, 2011, 118, 2718-2718.	1.4	2
277	A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study. Blood, 2012, 120, 1617-1617.	1.4	2
278	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. Blood, 2015, 126, 517-517.	1.4	2
279	Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2014, 32, 8503-8503.	1.6	2
280	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. Blood, 2014, 124, 2526-2526.	1.4	2
281	Hepatitis B Virus Associated B-Cell Non-Hodgkin Lymphoma in Non-Endemic Areas. Blood, 2018, 132, 4228-4228.	1.4	2
282	Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study. Blood, 2021, 138, 3533-3533.	1.4	2
283	Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study. Blood, 2021, 138, 1411-1411.	1.4	2
284	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. Cancers, 2022, 14, 791.	3.7	2
285	Mantle Cell Lymphoma. , 2015, , 233-243.		1
286	A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S248-S249.	0.4	1
287	Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors. Haematologica, 2021, 106, 593-596.	3.5	1
288	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). Journal of Physical Education and Sports Management, 2021, 7, a005934.	1.2	1

#	ARTICLE	IF	CITATIONS
289	CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma. Human Pathology, 2021, 111, 84-91.	2.0	1
290	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. Blood, 2014, 124, 1625-1625.	1.4	1
291	Promising Results of Ibrutinib in Three Patients with Secondary Central Nervous System Mantle Cell Lymphoma. Blood, 2014, 124, 3105-3105.	1.4	1
292	Analytical Performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with Diffuse Large B-Cell Lymphoma Core Needle Biopsy Samples. Blood, 2015, 126, 1481-1481.	1.4	1
293	Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group. Blood, 2016, 128, 2987-2987.	1.4	1
294	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. Journal of Clinical Oncology, 2016, 34, 7518-7518.	1.6	1
295	Tailoring treatment for MALT lymphoma patients: where do we stand now?. Oncotarget, 2017, 8, 114422-114423.	1.8	1
296	Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. Cancer, 2021, , .	4.1	1
297	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. Blood, 2011, 118, 502-502.	1.4	1
298	Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03-6B GELA Study.. Blood, 2012, 120, 2723-2723.	1.4	1
299	Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?. Blood, 2015, 126, 2886-2886.	1.4	1
300	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	1
301	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1
302	Actualités thérapeutiques dans les lymphomes. , 2013, , .		0
303	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. British Journal of Haematology, 2014, 164, 896-899.	2.5	0
304	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. Leukemia and Lymphoma, 2016, 57, 2425-2428.	1.3	0
305	TP53, XPO1 and ATM Mutations Exclusive Distribution in the Adverse Prognosis Chronic Lymphocytic Leukemia (CLL) Group. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S218.	0.4	0
306	High Frequency of Mutations in BTK and PLCG2 in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S217-S218.	0.4	0

#	ARTICLE	IF	CITATIONS
307	Hairy Cell Leukemia: Results of the French Retrospective Cohort After 10 Years of Follow Up. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S313-S314.	0.4	0
308	Specific renal infiltration by aggressive lymphoma mimicking tumor lysis syndrome. Intensive Care Medicine, 2020, 46, 123-124.	8.2	0
309	Aspects biologiques et thérapeutiques des lymphomes de la zone marginale. Revue Francophone Des Laboratoires, 2021, 2021, 56-63.	0.0	0
310	Splenic Marginal Zone Lymphoma. Hematologic Malignancies, 2021, , 127-142.	0.2	0
311	Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL). Blood, 2011, 118, 2673-2673.	1.4	0
312	Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome. Blood, 2012, 120, 1582-1582.	1.4	0
313	Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients. Blood, 2012, 120, 3921-3921.	1.4	0
314	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. Blood, 2013, 122, 3005-3005.	1.4	0
315	Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. Blood, 2013, 122, 2202-2202.	1.4	0
316	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	1.4	0
317	Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. Blood, 2013, 122, 3663-3663.	1.4	0
318	Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases. Blood, 2013, 122, 5308-5308.	1.4	0
319	First Lymphoma Study Association workshops Deauville (France), 10th-12th October 2013 – Apart 2. Hematologie, 2014, 20, 68-77.	0.0	0
320	A multicenter study of 66 patients with spinal cord compression at diagnosis of B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2014, 32, 8560-8560.	1.6	0
321	Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab.. Journal of Clinical Oncology, 2014, 32, e19541-e19541.	1.6	0
322	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study. Blood, 2014, 124, 1657-1657.	1.4	0
323	Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma. Blood, 2015, 126, 588-588.	1.4	0
324	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. Blood, 2016, 128, 927-927.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Tolerance and Efficacy of L-Asparaginase during Induction of Extra-Nodal Natural Killer (NK/T) Lymphoma, Nasal Type, in Real-Life Experience. Blood, 2016, 128, 5351-5351.	1.4	0
326	Abstract 5616: Rituximab chemotherapy induces a partial recovery from T-cell exhaustion in follicular lymphoma patients. , 2018, , .		0
327	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy â€” a Study By the Lysa Group. Blood, 2018, 132, 4099-4099.	1.4	0
328	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a LyMa-Genomic Project Conducted on Behalf of the Lysa Group. Blood, 2018, 132, 2846-2846.	1.4	0
329	Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study. Blood, 2018, 132, 4199-4199.	1.4	0
330	Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome. Blood, 2018, 132, 1569-1569.	1.4	0
331	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. Blood, 2021, 138, 3495-3495.	1.4	0
332	A Systematic Review and a Survey Both Reveal Wide Heterogeneity across Trials and Investigators on Time-to-Event Endpoints Definitions in Marginal Zone Lymphoma. Blood, 2021, 138, 4502-4502.	1.4	0
333	Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. Blood, 2020, 136, 42-42.	1.4	0
334	A Retrospective Study of 67 Inflammatory Waldenstr�m's Macroglobulinemia. Blood, 2020, 136, 14-15.	1.4	0
335	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts. HemaSphere, 2022, 6, e680.	2.7	0
336	Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma. Haematologica, 2022, , .	3.5	0
337	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. Cancers, 2022, 14, 1761.	3.7	0
338	Finding a consensus on timeâ€¢toâ€¢event endpoints definitions in marginal zone lymphoma: A Delphi method. Hematological Oncology, 2022, 40, 1086-1089.	1.7	0